FINWIRES · TerminalLIVE
FINWIRES

Silver Mountain Reports High-Grade Silver Results From Sampling Program Near Reliquias Mine, Peru

By

-- Silver Mountain Resources (AGMR.TO) reported high-grade silver results from brownfield exploration near the Reliquias Mine in central Peru, the company said on Monday.

Channel sampling along a 550-meter segment of the central portion of the Seguridad SE vein, 2.1 kilometres north of the Reliquias Mine, returned a weighted average grade of 2,003 grams per tonne (g/t) silver over an average true vein width of 0.45 meters. These results indicate that high-grade silver mineralization may remain open along strike, both at the Seguridad SE vein and in other nearby veins belonging to the same structural system, a statement noted.

Silver Mountain is currently evaluating areas surrounding the proposed Reliquias production centre.

"These results further validate our focus on near-mine brownfield exploration as a disciplined and cost-effective strategy. Identifying high-grade silver mineralization at surface, close to existing infrastructure, strengthens the overall value proposition of the Reliquias district and supports our longer-term objective of expanding the resource base as we advance toward a planned production restart," said chief executive Alvaro Espinoza.

Related Articles

Asia

Anteris Technologies Secures US Medicare Reimbursement Eligibility for PARADIGM Trial

Anteris Technologies (ASX:AVR) said it has secured US Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a Centers for Medicare and Medicaid Services (CMS) national coverage policy, according to a Wednesday Australian bourse filing.The PARADIGM Trial is evaluating the safety and effectiveness of the DurAVR transcatheter heart valve (THV) compared to transcatheter aortic valve replacements (TAVRs), with DurAVR THV being Anteris' product to treat aortic stenosis, a potentially life-threatening condition resulting from the narrowing of the aortic valve, the filing added.The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation.The company said that securing this reimbursement eligibility is expected to facilitate US site activation and accelerate operational momentum across participating centers.The company's shares rose 2% in recent Wednesday trade.

$ASX:AVR
Asia

Lancang River Hydropower's 2025 Profit Rises 3%, Revenue Climbs 7%

Huaneng Lancang River Hydropower's (SHA:600025) net profit attributable to shareholders for 2025 increased 2.5% to 8.50 billion yuan from 8.30 billion yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share rose 2.3% year on year to 0.45 yuan from 0.44 yuan.Operating revenue climbed 6.9% to 26.6 billion yuan from 24.9 billion yuan in the previous year.The hydropower company's shares fell 1% during the morning trade.

$SHA:600025
Asia

Shengyi Technology's Q1 Profit Doubles as Revenue Jumps 45%

Shengyi Technology (SHA:600183) reported a 105.5% jump in attributable net profit in the first quarter to 1.16 billion yuan from 563.6 billion yuan, according to a filing with the Shanghai bourse on Wednesday.Earnings per share doubled to 0.48 yuan from 0.24 yuan.Revenue jumped 45% to 8.14 billion yuan from 5.61 billion yuan, which the electronic components manufacturer attributed to pricing adjustment, among other factors.

$SHA:600183